Psoriasis, blog, experiences, bloggers, stories, beauty, grooming, skin, products

Help make a difference for your psoriasis patients: look below the surface

The PSO What? report challenges the myths and misconceptions about psoriasis and draws attention to the debilitating effect the condition can have on an individual’s emotional, mental and physical wellbeing, as well as the burden of its comorbidities. GPs play a unique role in assessing the whole patient, and are ideally placed to anticipate, prevent and manage the comorbidities associated with psoriasis, in order to reduce its broader burden.

This report shows that a third of patients with psoriasis do not visit their GP at least once a year to review their condition.1 Yet, people with psoriasis can be at risk of developing serious comorbidities,2 including psoriatic arthritis,2,3 cardiovascular disease,4,5 metabolic syndrome,6 inflammatory bowel disease,7 complications with vision8 and some cancers.9

Psoriasis is more than skin deep. Find out more about the main comorbidities associated with psoriasis.

Make TIME for psoriasis

The PSO What? report highlighted that regular holistic reviews are essential for the overall physical and mental health of patients living with psoriasis.1

Everyone with psoriasis should be offered regular reviews so that they receive personalised, effective treatment, meaningful information and care plans.1

This consultation guide, developed by LEO Pharma and based on the current NICE guidelines for the assessment and management of psoriasis (CG153),10 can support you in assessing the extent of your patient’s psoriasis, as well as the physical, psychological and social impact, in the short time of your consultation.

The PSO What? initiative is a partnership programme led by the Patients Association and LEO Pharma, in collaboration with the expert PSO What? Taskforce. LEO Pharma has provided core funding, editorial input and undertaken survey-based research to support the development of the PSO What? Report.

This content is intended for UK and IE Healthcare Professionals


1. Data on file. LEO Pharma. DERM-004 MAR 2017
2. World Health Organization. Global report on psoriasis 2016, 2016
3. NHS Choices. Psoriatic Arthritis Overview. Available at: (Last accessed August 2020)
4. Gelfand JM, Niemann AL, Shin DB et al. JAMA. 2016; 296:1735-41
5. Ahlehoff O, Gislason GH, Jorgenson CH, et al. Eur Heart J. 201;33:2054-64
6. Langan SM, Seminara NM, Shin DB, et al. J Invest Dermatol. 2012:132(Pt 1):555-62
7. Skroza N, Proletti I, Pampena R, et al. Biomed Med Int. 2013:article ID 983902
8. Fraga NA, Oliveira MF, Follador I, et al. An Bras Dermatol. 2012;87:877-83
9. Pouplard C, Brenaut E, Horreau C, et al. JEADV. 2013;27(Suppl 3):36-46
10. National Institute for Health and Care Excellence. Psoriasis: assessment and management. Algorithm. October 2012. Available from: cg153/evidence/algorithm-pdf-188351535 (Last accessed: 8th August 2020)
UK/IE/MAT-19540 – August 2020
You are now entering a website created by LEO Pharma in the UK and Ireland.

Scroll to top